- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors ; volume:17 ; number:1 ; day:23 ; month:8 ; year:2018 ; pages:1-14 ; date:12.2018
Molecular cancer ; 17, Heft 1 (23.8.2018), 1-14, 12.2018
- Urheber
-
Yi, Ming
- Beteiligte Personen und Organisationen
-
Jiao, Dechao
Xu, Hanxiao
Liu, Qian
Zhao, Weiheng
Han, Xinwei
Wu, Kongming
SpringerLink (Online service)
- DOI
-
10.1186/s12943-018-0864-3
- URN
-
urn:nbn:de:101:1-2018101805332463111319
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yi, Ming
- Jiao, Dechao
- Xu, Hanxiao
- Liu, Qian
- Zhao, Weiheng
- Han, Xinwei
- Wu, Kongming
- SpringerLink (Online service)
Ähnliche Objekte (12)
World-First Phase I Clinical Trial for CRISPR-Cas9 PD-1-Edited T-Cells in Advanced Nonsmall Cell Lung Cancer
PD-L1 degradation pathway and immunotherapy for cancer
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Comparing VIP and PD‐L1 expression as cancer biomarkers
Die klinisch-onkologische Bedeutung von Tumormarkern beim Mammakarzinom unter besonderer Berücksichtigung des mucin like carcinoma associated Antigen (MCA)
Laparoscopy-assisted Distal Gastrectomy should become a Standard Surgical Treatment Option for Stage IA/IB Gastric Cancer
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Regulatory mechanisms of PD-1/PD-L1 in cancers
World-First Phase I Clinical Trial for CRISPR-Cas9 PD-1-Edited T-Cells in Advanced Nonsmall Cell Lung Cancer
PD-L1 degradation pathway and immunotherapy for cancer
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Comparing VIP and PD‐L1 expression as cancer biomarkers
Die klinisch-onkologische Bedeutung von Tumormarkern beim Mammakarzinom unter besonderer Berücksichtigung des mucin like carcinoma associated Antigen (MCA)
Laparoscopy-assisted Distal Gastrectomy should become a Standard Surgical Treatment Option for Stage IA/IB Gastric Cancer
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Regulatory mechanisms of PD-1/PD-L1 in cancers
World-First Phase I Clinical Trial for CRISPR-Cas9 PD-1-Edited T-Cells in Advanced Nonsmall Cell Lung Cancer
PD-L1 degradation pathway and immunotherapy for cancer
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Comparing VIP and PD‐L1 expression as cancer biomarkers
Die klinisch-onkologische Bedeutung von Tumormarkern beim Mammakarzinom unter besonderer Berücksichtigung des mucin like carcinoma associated Antigen (MCA)
Laparoscopy-assisted Distal Gastrectomy should become a Standard Surgical Treatment Option for Stage IA/IB Gastric Cancer
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway